Ling Yang
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
Papers in
-
- RNA modifications and cancer 5
- Epidemiology 11
- Liver Disease Diagnosis and Treatment 6
- Adipokines, Inflammation, and Metabolic Diseases 4
- Co-authors
- Xiangbo Ruan (5 shared papers)Haiming Cao (4 shared papers)Ping Li (4 shared papers)Jun Zhu (2 shared papers)Takuji Okusaka (6 shared papers)Andrew X. Zhu (6 shared papers)Jonathan D. Schwartz (2 shared papers)Masatoshi Kudo (6 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)PLoS ONE (3 papers)Cell Metabolism (2 papers)Scientific Reports (2 papers)Journal of Hepatology (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Ling Yang
44 papers receiving 1.7k citations
Ling Yang's Hit Papers
Peers
Comparison fields: 5 of 99
- Hepatology 586
- Cancer Research 543
- Pathology and Forensic Medicine 273
- Epidemiology 413
- Oncology 293
Countries citing papers authored by Ling Yang
This map shows the geographic impact of Ling Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Yang more than expected).
Fields of papers citing papers by Ling Yang
This network shows the impact of papers produced by Ling Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Yang. The network helps show where Ling Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Ling Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Hit paper breakdown → | 2015 | 634 |
| 2 | 2015 | 237 | |
| 3 | 2010 | 132 | |
| 4 | 2016 | 91 | |
| 5 | 2021 | 89 | |
| 6 | 2010 | 84 | |
| 7 | 2016 | 59 | |
| 8 | 2015 | 46 | |
| 9 | 2006 | 37 | |
| 10 | 2011 | 30 | |
| 11 | 2011 | 30 | |
| 12 | 2021 | 29 | |
| 13 | 2015 | 29 | |
| 14 | 2015 | 24 | |
| 15 | 2017 | 21 | |
| 16 | 2018 | 18 | |
| 17 | 2019 | 15 | |
| 18 | 2021 | 15 | |
| 19 | 2021 | 14 | |
| 20 | 2023 | 13 |
About Ling Yang
Ling Yang is a scholar working on Molecular Biology, Epidemiology, Physiology, Hepatology and Cancer Research, having authored 50 papers that have together received 1.8k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cancer-related molecular mechanisms research (7 papers), Liver Disease Diagnosis and Treatment (6 papers), RNA modifications and cancer (5 papers), Adipokines, Inflammation, and Metabolic Diseases (4 papers), Lipid metabolism and disorders (4 papers), Liver physiology and pathology (3 papers) and Cancer Mechanisms and Therapy (3 papers). The work is most often cited by research in Hepatology (586 citations), Cancer Research (543 citations), Pathology and Forensic Medicine (273 citations), Epidemiology (413 citations) and Oncology (293 citations). Ling Yang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Xiangbo Ruan, Haiming Cao, Ping Li, Jun Zhu, Takuji Okusaka, Andrew X. Zhu, Jonathan D. Schwartz, Masatoshi Kudo, Paolo Abada and Chia-Jui Yen. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE, Cell Metabolism, Scientific Reports and Journal of Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.